Robyn Karnauskas
Stock Analyst at Truist Securities
(1.92)
# 3,185
Out of 5,117 analysts
178
Total ratings
43.79%
Success rate
-0.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,038 → $1,182 | $1,077.75 | +9.67% | 6 | Nov 19, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $3.58 | +179.33% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $332.93 | -10.49% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $54.64 | +18.96% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $106.78 | +3.02% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $124.70 | -33.44% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $229.98 | -8.69% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.32 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $177.08 | +92.00% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $1.06 | +2,352.83% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.33 | +426.32% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $784.97 | +44.59% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.93 | +418.13% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $3.57 | +152.10% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $22.23 | +3.46% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $26.16 | +83.49% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $23.09 | +116.54% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $462.90 | +9.74% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $25.09 | +43.48% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $78.52 | -68.16% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.66 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $59.95 | +133.53% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $3.31 | +906,244.41% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.00 | +600.00% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $24.81 | +121.68% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $11.31 | +2,729.35% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $29.89 | -49.82% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.11 | +74,526.87% | 1 | Oct 8, 2020 |
Eli Lilly and Company
Nov 19, 2025
Maintains: Buy
Price Target: $1,038 → $1,182
Current: $1,077.75
Upside: +9.67%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $3.58
Upside: +179.33%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $332.93
Upside: -10.49%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $54.64
Upside: +18.96%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $106.78
Upside: +3.02%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $124.70
Upside: -33.44%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $229.98
Upside: -8.69%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.32
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $177.08
Upside: +92.00%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.06
Upside: +2,352.83%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.33
Upside: +426.32%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $784.97
Upside: +44.59%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.93
Upside: +418.13%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $3.57
Upside: +152.10%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $22.23
Upside: +3.46%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $26.16
Upside: +83.49%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $23.09
Upside: +116.54%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $462.90
Upside: +9.74%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $25.09
Upside: +43.48%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $78.52
Upside: -68.16%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.66
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $59.95
Upside: +133.53%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $3.31
Upside: +906,244.41%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.00
Upside: +600.00%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $24.81
Upside: +121.68%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $11.31
Upside: +2,729.35%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $29.89
Upside: -49.82%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.11
Upside: +74,526.87%